Herbal Dispatch Past Earnings Performance
Past criteria checks 0/6
Herbal Dispatch has been growing earnings at an average annual rate of 52.4%, while the Pharmaceuticals industry saw earnings growing at 43.4% annually. Revenues have been growing at an average rate of 77.9% per year.
Key information
52.4%
Earnings growth rate
62.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 77.9% |
| Return on equity | -44.7% |
| Net Margin | -16.2% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How Herbal Dispatch makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 10 | -2 | 3 | 0 |
| 30 Jun 24 | 8 | -2 | 3 | 0 |
| 31 Mar 24 | 6 | -2 | 3 | 0 |
| 31 Dec 23 | 5 | -2 | 3 | 0 |
| 30 Sep 23 | 3 | -4 | 3 | 0 |
| 30 Jun 23 | 2 | -4 | 3 | 0 |
| 31 Mar 23 | 1 | -5 | 3 | 0 |
| 31 Dec 22 | 0 | -5 | 2 | 0 |
| 30 Sep 22 | 0 | -2 | 3 | 0 |
| 30 Jun 22 | 0 | -2 | 2 | 0 |
| 31 Mar 22 | 1 | -2 | 3 | 0 |
| 31 Dec 21 | 1 | -2 | 3 | 0 |
| 30 Sep 21 | 1 | -5 | 3 | 0 |
| 30 Jun 21 | 0 | -4 | 2 | 0 |
| 31 Mar 21 | 0 | -5 | 2 | 0 |
| 31 Dec 20 | 0 | -6 | 3 | 0 |
| 30 Sep 20 | 0 | -19 | 5 | 0 |
| 30 Jun 20 | 0 | -21 | 7 | 0 |
| 31 Mar 20 | 0 | -23 | 7 | 0 |
| 31 Dec 19 | 1 | -22 | 9 | 0 |
| 30 Sep 19 | -2 | -16 | 10 | 1 |
| 31 Dec 18 | 3 | -30 | 17 | 1 |
| 31 May 18 | 10 | -14 | 11 | 0 |
| 28 Feb 18 | 11 | -10 | 8 | 0 |
| 31 May 17 | 5 | -3 | 3 | 0 |
| 31 May 16 | 1 | -2 | 1 | 0 |
Quality Earnings: HERB is currently unprofitable.
Growing Profit Margin: HERB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HERB is unprofitable, but has reduced losses over the past 5 years at a rate of 52.4% per year.
Accelerating Growth: Unable to compare HERB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HERB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-44%).
Return on Equity
High ROE: HERB has a negative Return on Equity (-44.68%), as it is currently unprofitable.